- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07223021
En undersøgelse af Fludarabin-dosering hos børn og unge voksne med B-celle akut lymfatisk leukæmi
Forbedring af hændelsesfri overlevelse ved optimering af FLUdarabin-eksponering under lymfodepletering for CAR T-celleterapi: en randomiseret, multicentrisk undersøgelse af børn og unge voksne med B-celle akut lymfatisk leukæmi (INFLUENCE)
The researchers are doing this study to find out whether PK-targeted fludarabine is an effective Lymphodepletion (LD) chemotherapy approach for people with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) who will receive tisagenlecleucel CAR T-cell therapy. The researchers will compare PK-targeted fludarabine dosing with standard fludarabine dosing to see which treatment approach is more effective. The researchers will also look at whether PK-targeted fludarabine dosing is feasible (practical), the side effects of the study treatment, and how the study treatment affects people's quality of life. The researchers will measure quality of life by having participants complete questionnaires.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: Kevin Curran, MD
- Telefonnummer: 1-833-MSK-KIDS
- E-mail: currank@mskcc.org
Undersøgelse Kontakt Backup
- Navn: Jaap Jan Boelens, MD, PhD
- Telefonnummer: 1-833-MSK-KIDS
Studiesteder
-
-
New York
-
New York, New York, Forenede Stater, 10065
- Rekruttering
- Memorial Sloan Kettering Cancer Center
-
Ledende efterforsker:
- Kevin Curran, MD
-
Kontakt:
- Kevin Curran, MD
- Telefonnummer: 1-833-MSK-KIDS
-
Kontakt:
- Jaap Jan Boelens, MD,PhD
- Telefonnummer: 1-833-MSK-KIDS
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45229
- Rekruttering
- Cincinnati Children's Hospital Medical Center
-
Kontakt:
- Christine Phillips, MD
- Telefonnummer: 513-636-4266
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Rekruttering
- Children's Hospital of Philadelphia
-
Kontakt:
- Regina Myers, MD
- Telefonnummer: 267-426-0762
-
-
Tennessee
-
Memphis, Tennessee, Forenede Stater, 38105
- Ikke rekrutterer endnu
- St. Jude Children's Research Hospital
-
Kontakt:
- Aimee Talleur, MD
- Telefonnummer: 901-595-4215
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- Texas Children's Hospital
-
Kontakt:
- Rayne Rouce, M.D., B.S.
- Telefonnummer: 832-822-4242
-
-
-
-
-
Utrecht, Holland
- Rekruttering
- Prinses Máxima Centrum
-
Kontakt:
- Friso Calkoen, MD
- Telefonnummer: +31 88 972 7272
-
-
-
-
-
Münster, Tyskland
- Rekruttering
- University Children's Hospital Münster
-
Kontakt:
- Claudia Rossig, MD
- Telefonnummer: +49 17641091917
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Patients with B-ALL and eligible to receive commercial tisagenlecleucel.
-
Patient's weight > 9 kg at time of lymphodepleting chemotherapy
-
Adequate organ function at time of LD is required and is defined:
- Hepatic: Serum bilirubin ≤ 2 mg/dL, unless benign congenital hyperbilirubinemia
- Hepatic: AST and ALT < 5x the upper limit of normal for age, unless thought to be leukemic disease-related
- Renal: Calculated glomerular filtration rate (GFR) ≥ 70 ml/min/1.73m^2. (based on Schwartz formula GFR (mL/min/1.73 m²) = (36.2 × Height in cm) / Creatinine in mg/dL
- Cardiac: LVEF ≥ 50% by multi-gated acquisition scan (MUGA), resting echocardiogram, or cardiac magnetic resonance imaging (MRI) within 6 weeks of screening
- Pulmonary: Oxygen saturation as recorded by pulse oximetry of ≥ 90% on room air
-
Adequate performance status:
- Age ≥ 16 years: ECOG ≤ 1 or Karnofsky > 60% at treatment
- Age < 16 years: Lansky ≥ 60% at treatment
-
Willing to participate as research subject and provide written informed consent from parents/legal representative, patient, and age-appropriate assent as appropriate before any study specific screening procedures are conducted, according to local, regional or national law and legislation.
Exclusion Criteria:
- Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to the study drugs, or drugs chemically related to study treatment or excipients that contraindicate their participation, including fludarabine, cyclophosphamide and tisagenlecleucel.
- Patients with tisagenlecleucel that is deemed out of specification (OOS) will be excluded from this protocol
- Clinically significant active and uncontrolled infection confirmed by clinical evidence, imaging, or positive laboratory tests (e.g., blood cultures, PCR for DNA/RNA etc.)
- Patient/parent/guardian unable to give informed consent or unable to comply with the treatment protocol.
- Pregnant or lactating women
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Standard Fludarabine regimen followed by CAR-T
Fludarabine 30 mg/m2/dose x 4 doses on days -6 to -3 (or -7 to -4) |
Fludarabine 30 mg/m2/dose x 4 doses on days -6 to -3 (or -7 to -4) All patients will receive Cyclophosphamide 500 mg/m2 IV on days -6 and -5 (or -7 and -6). Targeted fludarabine LD: Fludarabine 40 mg/m2/dose x 2 doses on days -6 and -5 (or -7 and -6), with doses on days -4 and -3 (or -5 and -4, if starting lymphodepletion on day -7) adjusted based on PK analysis to target a cumulative area under the curve (AUC) of 18 mg*h/L (range 17.5-18.5mg*h/L) will be infused based on institutional guidelines. |
|
Eksperimentel: Targeted fludarabine regimen followed by CAR-T
Fludarabine 40 mg/m2/dose x 2 doses on days -6 and -5 (or -7 and -6), with doses on days -4 and -3 (or -5 and -4, if starting lymphodepletion on day -7) adjusted based on PK analysis to target a cumulative area under the curve (AUC) of 18 mg*h/L (range 17.5-18.5mg*h/L |
Fludarabine 30 mg/m2/dose x 4 doses on days -6 to -3 (or -7 to -4) All patients will receive Cyclophosphamide 500 mg/m2 IV on days -6 and -5 (or -7 and -6). Targeted fludarabine LD: Fludarabine 40 mg/m2/dose x 2 doses on days -6 and -5 (or -7 and -6), with doses on days -4 and -3 (or -5 and -4, if starting lymphodepletion on day -7) adjusted based on PK analysis to target a cumulative area under the curve (AUC) of 18 mg*h/L (range 17.5-18.5mg*h/L) will be infused based on institutional guidelines. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
compare the event free survival (EFS )
Tidsramme: 28 days
|
EFS is defined as time from randomization until non-response at day 28 after CAR T cell infusion, loss of B-cell aplasia <6 months from the time of CAR T cell infusion, disease relapse, initiation of anti-leukemic therapy or death of any cause |
28 days
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
overlevelse
Tidsramme: 2 år
|
2 år
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Kevin Curran, MD, Memorial Sloan Kettering Cancer Center
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Neoplasmer
- Sygdomme i immunsystemet
- Infektioner
- Virussygdomme
- Neoplasmer efter histologisk type
- DNA-virusinfektioner
- Lymfesygdomme
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Lymfom, Non-Hodgkin
- Lymfom, B-celle
- Lymfom
- Epstein-Barr-virusinfektioner
- Herpesviridae infektioner
- Tumorvirusinfektioner
- Hemiske og lymfatiske sygdomme
- Burkitt lymfom
- Organiske kemikalier
- Kulbrinter
- Fosforamid -sennep
- Nitrogen sennepsforbindelser
- Sennepsforbindelser
- Kulbrinter, halogeneret
- Phosphoramider
- Organophosphorforbindelser
- Cyclofosfamid
- fludarabin
Andre undersøgelses-id-numre
- 25-072
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .